PT - JOURNAL ARTICLE AU - Mukhtar, Khalid AU - Qassim, Suelen AU - Al Qahtani, Shaikha Ali AU - Danjuma, Mohamed Ibn-Masud AU - Mohamedali, Mohamed AU - Farhan, Housamaddeen Al AU - Khudair, Mohammed F. AU - El Tayeh, Abdel Rehim AU - Al-Dosari, Mohammed AU - Babiker, Mohamed Elhassan AU - Hassib, Ahmed AU - Elmustafa, Rumaisa Mohamed AU - Elhadary, Wesal AU - Abdulkarim, Morwan AU - Singh, Rajvir AU - Al.Maslamani, Muna TI - A randomized trial on the regular use of potent mouthwash in COVID-19 treatment AID - 10.1101/2020.11.27.20234997 DP - 2021 Jan 01 TA - medRxiv PG - 2020.11.27.20234997 4099 - http://medrxiv.org/content/early/2021/04/25/2020.11.27.20234997.short 4100 - http://medrxiv.org/content/early/2021/04/25/2020.11.27.20234997.full AB - In this work we tried to study the effect of the regular use of potent mouthwash in COVID19 cases, on the premise that it may speedup the recovery, through the repeated reduction of microbial load, of both, the 2019-nCOV and oral microbiota; thus slowing the disease progression and lowering the incidence of superinfections.Through a randomized controlled trial, a mixed solution of Hydrogen peroxide 2% and chlorhexidine gluconate, to be used for oral rinsing and gargling three times daily, was tested in cases admitted to COVID treatment facility, versus the standard (only) COVID19-treatment protocol, starting with 46 cases in each group, matched in terms of disease severity, of symptoms, and average cycle threshold value (CT-value) for the COVID PCR test on diagnosis.Our findings showed statistically significant improvement in terms of a higher conversion rate to “COVID19-negative PCR” by five days of treatment (6/46 Vs 0/46), improvement in “symptoms severity” after two days of treatment, and less intubation and mortality (0/46 Vs 3/46) with all P-value < 0.05. There was also a trend of improvement in other outcome variables, though with no statistically significant difference; namely “shorter hospital stays,” “less progression in Oxygen requirements”, “less rate of plasma transfusion”, and better “gross extent of improvement”.Our findings support a beneficial role in treating active cases (Disease) and anticipates better outcome should implemented earlier in course of the disease; thus, suggest a role in limiting the spread (Pandemic), as an additional preventive method. Additionally, we think the repeated reduction in the microbial load might have been sufficient to induce a strain in a possible viral-microbial interaction, resulting in slowing down of the disease progress.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN10197987 https://doi.org/10.1186/ISRCTN10197987Funding StatementThe study is funded by Hamad Medical Corporation’s Medical Research CenterAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Hamad Medical Corporation - Medical Research Center- IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Data sheet referenced in the manuscript is to be shared only with a publishing journal, after signing a Data sharing agreement https://www.isrctn.com/ISRCTN10197987 RTIRespiratory Tract InfectionCOVID19novel Coronavirus disease 20192019-nCOVthe novel coronavirus that causes severe acute respiratory illness/ SyndromeRT-PCRReverse transcription Polymerase Chain reactionCTCycle threshold value; the number of amplification cycles required to reach a fixed (fluorescent) signal to cross the threshold (i.e., exceeds background level).